In a recent update, Needham analyst Gil Blum has maintained a "Buy" rating on CRISPR Therapeutics (CRSP, Financial), despite a decrease in the price target. The target price has been lowered from USD 84.00 to USD 81.00, representing a -3.57% change.
This move comes as part of Needham's ongoing assessment of CRISPR Therapeutics (CRSP, Financial), which continues to be a point of interest for investors. The decision to maintain the "Buy" rating suggests confidence in the company's future performance, even with the adjusted price expectations.
The current analyst action reflects the firm's belief in CRISPR Therapeutics' (CRSP, Financial) potential within the biotechnology sector, despite the recent price target adjustment. Investors may want to consider this endorsement as they evaluate their portfolios.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 24 analysts, the average target price for CRISPR Therapeutics AG (CRSP, Financial) is $81.00 with a high estimate of $268.00 and a low estimate of $32.00. The average target implies an upside of 144.27% from the current price of $33.16. More detailed estimate data can be found on the CRISPR Therapeutics AG (CRSP) Forecast page.
Based on the consensus recommendation from 28 brokerage firms, CRISPR Therapeutics AG's (CRSP, Financial) average brokerage recommendation is currently 2.3, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for CRISPR Therapeutics AG (CRSP, Financial) in one year is $27.42, suggesting a downside of 17.31% from the current price of $33.16. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the CRISPR Therapeutics AG (CRSP) Summary page.
